Back to the Scottish Parliament Petition 1296 (pdf size 58 KB posted 20.11.2009)
Archive Home

Business Bulletin 1999-2011

Minutes of Proceedings 1999-2011

Journal of Parliamentary Proceedings Sessions 1 & 2

Committees Sessions 1, 2 & 3

Annual reports

Petition by Robert Thomson  
 
Closed Petitions - Petition PE1296  
Petition by Robert Thomson on behalf of LDN Now Scotland calling on the Scottish Parliament to urge the Scottish Government to make Low Dose Naltrexone readily available on the NHS to auto-immune disease sufferers as well as other conditions not classified as auto-immune such as HIV/AIDS, cancer and fertility, in each NHS board area thereby reducing the danger of sufferers having to access riskier alternatives and also incurring higher costs by purchasing the drug through private medical providers and to provide guidance to all GPs on LDN protocol and require them to collect LDN clinical data.  
Petitioner: Robert Thomson  
On behalf of: LDN Now Scotland 
Number of signatures: 1201  
Date lodged: 20 November 2009  
SPICe Briefing: Briefing for PE1296 
Summary:

Written Questions for PE1296  

Written Submissions for PE1296  

Link to e-petition  

1 December 2009 :   The Committee took evidence from Bob Thomson, Celia Danks and Margaret Anne Gachagan and agreed to write to the Scottish Government, Scottish Medicines Consortium, NHS Quality Improvement Scotland,a selection of NHS Boards (Greater Glasgow and Clyde, Lanarkshire and Tayside), the Essential Health Clinic, LDN Research Trust, MS Society, Cancer Research UK, Alzheimer's Society, National Association for Colitis and Crohn's Disease, Association of the British Pharmaceutical Industry, the Royal Pharmaceutical Society of Great Britain, the National Institute for Clinical Excellence and Penn State University (USA) seeking responses to the points raised in the petition and during the discussion. <Link to Official Report 1 December 2009 

2 March 2010 :   The Committee agreed to write to the Scottish Government and the Department of Health seeking a response to specific points. <Link to Official Report 2 March 2010 

1 June 2010 :   The Committee agreed to write to the Scottish Government seeking a response to specific points. <Link to Official Report 26 January 2010" 

23 November 2010 :   The Committee agreed to write to the Scottish Government seeking a response to specific points. Link to Official Report 23 November 2010" 

8 February 2011 :   The Committee agreed to invite the Cabinet Secretary for Health and Wellbeing to give oral evidence and to write to the Scottish Government seeking a response to specific points. <Link to Official Report 8 February 2011 

1 March 2011 :   The Committee heard evidence from Professor Bill Scott, Chief Pharmaceutical Officer; Dr Alan McNair, Research Manager; and Peter Craig, Research Manager, Scottish Government and agreed to close the petition under Rule 15.7 of Standing Orders on the grounds that the Committee has facilitated a meeting between the petitioner and Scottish Government officials to discuss the issues raised in the petition. The Scottish Government has also responded to the Committee's request to assist with an application for a LDN/MS trial. Further, it has suggested a number of options to assist patients, patient groups and health professionals to contact researchers and get them interested in LDN research and if any research results showed a significant benefit then more research activity would be attracted to this area. Link to Official Report 1 March 2011" 

 
Public Petitions Committee Home Page